clinical trial · NCT06827145
Combination of Vebreltinib and Osimertinib in Patients with EGFR 21 L858R Mutation Advanced NSCLC
National Cancer Center, China·phase2·active not recruiting·n = 30
Non-Small-Cell Lung CancerVebreltinibOsimertinib
brief summary
This is a Prospective, open label, single arm study to evaluate the efficacy and safety of Vebreltinib combined with Osimertinib in the treatment of locally advanced or metastatic non-small cell lung cancer with EGFR 21 L858R mutation
started
Oct 14, 2024
primary completion
Sep 1, 2026
completion
Sep 1, 2028
last updated
Feb 14, 2025
official title
An Open-label, Single-center, Single-arm Phase IIa Study to Evaluate the Safety and Efficacy of Vebreltinib in Combination with Osimertinib in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer with EGFR 21 L858R Mutation
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol